Injecting Reality into Commercial Due Diligence for In-Licensing, Partnering or Purchasing Pharmaceutical Assets in Development

When performing due diligence for in-licensing, partnering or purchasing pharmaceutical assets in development, pharmaceutical and biotech companies evaluate the asset based on factors including the scientific data available, intellectual property of the asset, clinical development plan, competitive analysis of the commercial opportunity for the asset and a financial analysis related to revenue projections.
Companies may attempt to complete this effort on their own or they may choose to use outside consulting firms to assist with components of the due diligence process.
This webinar will focus on how pharmaceutical and biotech companies can inject reality into the commercial opportunity analysis by measuring expected physician demand for the drug to inform revenue projections and decisions about in-licensing, partnering or purchasing these assets.